3D model (JSmol)
|Molar mass||919.95 g/mol|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
beta-Amanitin or β-amanitin is a cyclic peptide comprising eight amino acids. It is part of a group of toxins called amatoxins, which can be found in several mushrooms belonging to the genus Amanita. Some examples are the death cap (Amanita phalloides) and members of the destroying angel complex, which includes A. virosa and A. bisporigera. Due to the presence of α-amanitin, β-amanitin, γ-amanitin and ε-amanitin these mushrooms are highly lethal to human beings.
The lethal dose of amanitoxins is 0.1 mg/kg of body weight of humans. The average Amanita mushroom contains 3–5 mg of amanitoxins, so one 40–50 g mushroom could kill an average adult. The U.S. Occupational Safety and Health Administration (OSHA) permits a time-weighted average exposure of up to 5 mg/m3 of β-amanitin dust.
Symptoms of exposure
β-amanitin may cause irritation of the respiratory tract, headache, dizziness, nausea, shortness of breath, coughing, insomnia, diarrhea, gastrointestinal disturbances, back pain, urinary frequency, liver and kidney damage, or death if ingested or inhaled. If β-amanitin comes in contact with skin, it may cause irritation, burns, redness, severe pain, and could be absorbed through the skin, causing similar effects to exposure via inhalation and ingestion. Contact with the eyes may result in irritation, corneal burns, and eye damage. Persons with pre-existing skin, eye, or central nervous systems disorders, impaired liver, kidney, or pulmonary function may be more susceptible to the effects of this substance.
Physiological mechanism of action
β-amanitin is able to travel through the bloodstream to reach the organs in the body. While it damages all organs, damage to the liver and heart result in fatalities. At the molecular level amanitin toxins cause damage to cells of these organs. The toxins may also cause disruptions in the plasma membranes resulting in organelles that are normally in the cytoplasm to be found in the extracellular matrix. beta-Amanitin is also an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, and as a result, mammalian protein synthesis. It has not been found to inhibit RNA polymerase I or bacterial RNA polymerase. Because it inactivates the RNA polymerases, the liver is unable to repair the damage that beta-amanitin causes and the cells of the liver disintegrate and the liver dissolves.
Due to its lethality and its widespread presence in the genus Amanita, which is found across the globe, β-amanitin has been extensively studied in the field of protein biochemistry. In particular, William Lipscomb, Nobel laureate, greatly contributed to characterizing this protein. Not only did Lipscomb determine how to successfully retrieve and purify this life-threatening protein, but he also determined the molecular structure by X-ray crystallography in a time before this technique was widely utilized.
Collection and purification
Due to its extreme lethality, as well as it being only commercially available at certain times and then at an extremely high cost, Amanita phalloides had to be retrieved from the wild in order to collect the β-amanitin protein. This was first achieved by collecting Amanita phalloides fruiting bodies in New Jersey in 1975. These mushrooms were then dried for 24 hours and then ground in a blender with water. The slurry created was homogenized further to break open any intact cells, and after this a brown syrup extract containing the toxins was collected. This extract was then taken through various separation methods to isolate the toxins themselves. The toxins were then desalted and taken through four different methods of sephadex and acidic protein purification.
The structure of β-amanitin was determined using X-ray crystallography. The crystallization and analysis were performed by Edward C. Kostansek and William H. Lipscomb in 1978. They crystallized β-amanitin by dissolving a purified sample in almost pure ethanol in a round bottom flask. The flask was left open overnight and crystals formed as the ethanol evaporated. This is considered to be an incredibly easy crystallization to perform.
- G. Shoham; D.C. Rees; W.N. Lipscomb; G. Zanotti; Th. Wieland (1984). "Crystal and Molecular Structure of S-Deoxo[Ile3]amaninamide: A synthetic Analogue of Amanita Toxins". Journal of the American Chemical Society. 106: 4606–4615. doi:10.1021/ja00328a051.
- "β-amanitin", Retrieved on 12 March 2013.
- "Material Safety Data Sheet for beta Amanitin"[permanent dead link], Retrieved on 12 March 2013.
- J. Meldolesi; G. Pelosi; A. Brunelli; E. Genovese (1966). "Electron Microscopic Studies on the Effects of Amanitin in Mice: Liver and Heart Lesions". Virchows Archiv A. 342: 221–235. doi:10.1007/bf00960591.
- "β-Amanitin from Amanita phalloides", Retrieved on 12 March 2013.
- "Polypeptide Toxins in Amanita Mushrooms", "Cornell University", Retrieved on 12 March 2013.
- E.C. Kostansek; W.N. Lipscomb; R.R. Yocum; W.E. Thiessen (1978). "Conformation of the Mushroom Toxin β-amanitin in the Crystalline State". Biochemistry. 17: 3790–3795. doi:10.1021/bi00611a019.
- R. Rogers Yocum (1978). "New Laboratory Scale Purification of & Amanitin from American Amanit a phalloides". Biochemistry. 17: 3786–3789. doi:10.1021/bi00611a018.